Caroline W Reiss

Verve Therapeutics, Cambridge, MA, USA.

5 publications 2017 – 2021 ORCID

What does Caroline W Reiss research?

Dr. Reiss studies how gene editing, particularly using a tool called CRISPR, can help lower cholesterol levels in a safe and durable way. Her research specifically looks at a gene named PCSK9, which plays a significant role in controlling cholesterol production in the liver. By editing this gene in primates, she is exploring a breakthrough method that could lead to a one-time treatment option for heart disease patients, which would replace the need for daily cholesterol medications.

Key findings

  • A single injection of CRISPR targeting the PCSK9 gene resulted in a cholesterol reduction of about 60% in primates.
  • The cholesterol levels remained significantly low for at least 8 months after the initial treatment.
  • This approach could potentially eliminate the need for lifelong cholesterol medications for heart disease patients.

Frequently asked questions

Does Dr. Reiss study heart disease?
Yes, she focuses on gene editing techniques that can help lower cholesterol, which is a key factor in heart disease.
What treatments has Dr. Reiss researched?
She has researched the use of CRISPR gene editing to provide a long-lasting treatment for high cholesterol.
Is Dr. Reiss's work relevant to patients with high cholesterol?
Absolutely. Her research could lead to new treatments that would help patients manage their cholesterol levels effectively without lifelong medication.

Publications in plain English

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.

2021

Nature

Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE +37 more

Plain English
Researchers used a gene-editing tool called CRISPR to permanently disable a gene in monkeys' livers that controls cholesterol production, delivering it through tiny fat particles injected into the bloodstream. After a single injection, the monkeys' cholesterol dropped by about 60% and stayed low for at least 8 months without any additional treatment. This proves that gene editing could offer heart disease patients a one-time treatment instead of taking cholesterol drugs for life.

PubMed

A Modular RNA Domain That Confers Differential Ligand Specificity.

2020

Biochemistry

Knappenberger AJ, Reiss CW, Focht CM, Strobel SA

Plain English
This study focused on RNA molecules known as aptamers, which can bind to different types of small chemicals. Researchers found that these RNA aptamers can be modified to change which chemicals they bind to by swapping parts of their structure and making a small change in one area. Specifically, they successfully switched the binding ability of two aptamers, showing that the parts of the RNA that interact with chemicals are modular and flexible, much like proteins. Who this helps: This benefits researchers and scientists looking for ways to create targeted therapies using RNA.

PubMed

Structures of two aptamers with differing ligand specificity reveal ruggedness in the functional landscape of RNA.

2018

eLife

Knappenberger AJ, Reiss CW, Strobel SA

Plain English
Researchers studied two types of RNA molecules known as riboswitches, which help regulate cellular processes by binding to different chemicals. They found that a small change in one of these RNA molecules (the G96A mutant) allowed it to prefer a different chemical (ppGpp) over its original target (PRPP), with a huge change in preference of 40,000 times. This discovery shows how easily RNA can evolve and adapt to new functions, which is important for understanding how genetic materials work and can be used in medicine. Who this helps: This benefits researchers and scientists working on RNA-based therapies and genetic engineering.

PubMed

Structural Basis for Ligand Binding to the Guanidine-I Riboswitch.

2017

Structure (London, England : 1993)

Reiss CW, Xiong Y, Strobel SA

Plain English
This study examined how a specific part of RNA, called the guanidine-I riboswitch, interacts with a molecule known as guanidinium found in certain bacteria. Researchers discovered the riboswitch's structure, revealing how it tightly binds to guanidinium while ignoring similar substances like the amino acid arginine. This specificity is crucial for regulating processes like nitrogen metabolism and drug resistance in bacteria. Who this helps: This benefits researchers and doctors working on bacterial infections and antibiotic resistance.

PubMed

Structural basis for ligand binding to the guanidine-II riboswitch.

2017

RNA (New York, N.Y.)

Reiss CW, Strobel SA

Plain English
This study looked at a specific RNA structure called the guanidine-II riboswitch found in bacteria, which helps control the production of certain genes by binding to a molecule called guanidine. Researchers discovered the precise shape of this riboswitch when it is attached to guanidine, revealing that it binds two guanidine molecules through several key interactions. This is important because understanding how these riboswitches work can help in developing new treatments targeting bacteria that rely on these systems. Who this helps: This helps researchers and medical professionals working on bacterial infections.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.